Scrobohaci M L, Freyssinet J M
Laboratoire d'Hémostase, Hôpital Saint-Louis, Paris, France.
Pathol Biol (Paris). 1991 Sep;39(7):709-15.
Antiphospholipid antibodies (APA) are heterogeneous immunoglobulines of G, M or A classes with specificity directed towards anionic phospholipids. The APA are associated with a wide variety of diseases. They have been found to represent risk factor for development of arterial and/or veinous thrombosis. The APA would perturbed the biological activities of anionic phospholipid surface in a manner that could decrease the natural anti-coagulant pathway in order to lead to thrombosis. In the latter hypothesis APA would appear as a secondary response to the exposure of phospholipid "self antigens" by activated or damaged blood vascular cells by known stimuli able to induce thrombosis. In these cases APA would therefore constitute a marker of risk of thrombosis. The question which remains to be solved is if APA possess their own pathogenic potential or if they appear as the result of an up-stream pathological event known to be favourable to the development of thrombosis or if both mechanism are involved.
抗磷脂抗体（APA）是G、M或A类异质性免疫球蛋白，对阴离子磷脂具有特异性。APA与多种疾病相关。它们已被发现是动脉和/或静脉血栓形成的危险因素。APA会以一种可能降低天然抗凝途径从而导致血栓形成的方式干扰阴离子磷脂表面的生物活性。在后一种假设中，APA可能是已知能够诱导血栓形成的刺激使血管细胞活化或受损后，磷脂“自身抗原”暴露的继发反应。因此在这些情况下，APA将构成血栓形成风险的标志物。有待解决的问题是，APA是具有自身致病潜力，还是作为已知有利于血栓形成的上游病理事件的结果出现，或者两种机制都有涉及。
